Literature DB >> 22034632

Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS).

John Gallacher1, Peter Elwood, Janet Pickering, Antony Bayer, Mark Fish, Yoav Ben-Shlomo.   

Abstract

BACKGROUND: Benzodiazepine use is widespread in older people, although its benefit is uncertain. AIM: To investigate the long-term effect of benzodiazepine use upon dementia risk.
METHODS: A prospective cohort of men seen on five occasions over 22 years with full medication histories, repeat measures of cognitive function and a clinical diagnosis of dementia.
RESULTS: Of 1134 men with complete data, 103 (9.1%) had been taking benzodiazepines regularly at one or more phases. These men showed a marked increased incidence of dementia (OR=3.50, 95% CI 1.57 to 7.79, p=0.002), which persisted despite adjustment for psychological distress and other covariates. Men exposed in earlier phases showed a greater association than more recent exposure, counter to what one would expect if this was due to reverse causation, though we failed to demonstrate a dose-response effect with drug duration.
CONCLUSION: The taking of benzodiazepines is associated with an increased risk of dementia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22034632     DOI: 10.1136/jech-2011-200314

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  46 in total

1.  Continuing Versus New Prescriptions for Sedative-Hypnotic Medications: United States, 2005-2012.

Authors:  Christopher N Kaufmann; Adam P Spira; Colin A Depp; Ramin Mojtabai
Journal:  Am J Public Health       Date:  2016-09-15       Impact factor: 9.308

Review 2.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

3.  Anxiety symptoms and risk of dementia and mild cognitive impairment in the oldest old women.

Authors:  Ahmed M Kassem; Mary Ganguli; Kristine Yaffe; Joseph T Hanlon; Oscar L Lopez; John W Wilson; Kristine Ensrud; Jane A Cauley
Journal:  Aging Ment Health       Date:  2017-01-10       Impact factor: 3.658

4.  Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.

Authors:  Fabienne A Biétry; Alena M Pfeil; Oliver Reich; Matthias Schwenkglenks; Christoph R Meier
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

5.  Hypnotics and the Risks of Dementia.

Authors:  Walter James
Journal:  J Clin Sleep Med       Date:  2017-06-15       Impact factor: 4.062

Review 6. 

Authors:  Linda Lee; Tejal Patel; Frank Molnar; Dallas Seitz
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

Review 7.  Optimizing medications in older adults with cognitive impairment: Considerations for primary care clinicians.

Authors:  Linda Lee; Tejal Patel; Frank Molnar; Dallas Seitz
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

8.  Benzodiazepine Use and Cognitive Decline in Elderly With Normal Cognition.

Authors:  Yuhai Zhang; Xiao-Hua Zhou; Dana H Meranus; Linbo Wang; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Apr-Jun       Impact factor: 2.703

9.  Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.

Authors:  Lone Baandrup; Birgitte Fagerlund; Birte Glenthoj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-11       Impact factor: 5.270

10.  Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

Authors:  Ritva Lähteenmäki; Juha Puustinen; Tero Vahlberg; Alan Lyles; Pertti J Neuvonen; Markku Partinen; Ismo Räihä; Sirkka-Liisa Kivelä
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.